CME Group Inc. SEC filings document the financial results, governance matters and market-infrastructure disclosures of a derivatives exchange and clearing operator. Form 8-K reports cover quarterly and annual results, GAAP and non-GAAP measures, pricing disclosures, material agreements and other events tied to the company’s trading, clearing, benchmark and market data activities.
The filings also describe clearing-house liquidity arrangements, including amendments to a multi-currency secured credit facility used for temporary liquidity needs related to clearing obligations and collateral mechanics. Proxy materials cover executive compensation, pay-versus-performance data, shareholder voting matters and governance. Other event reports have addressed officer transition disclosures and legal matters involving CME Group and the Board of Trade of the City of Chicago.
CME Group Inc. (CME) reported total revenue of $1,737.3 million for the quarter ended September 30, 2026, up from $1,537.6 million a year earlier. Net income was $1,036.9 million versus $908.0 million, and diluted earnings per share were $2.89 versus $2.49. Clearing and transaction fees provided $1,378.1 million of quarterly revenue, while market data and information services contributed $243.1 million.
Average daily contract volume rose 16% to 29.445 million contracts. The average rate per contract fell 3% to $0.679; CME attributed the lower rate largely to higher volumes of lower-rate micro contracts and a greater share of member trading. Operating cash flow for the first nine months of 2026 was $3,292.9 million, compared with $3,143.2 million a year earlier.
During the first nine months of 2026, CME repurchased 6,432,010 Class A shares at an average $272.89 per share, for $1.8 billion excluding excise tax; $1.0 billion remained under the program as of September 30, 2026. Long-term debt was $3,425.1 million as of that date, and CME said it was in compliance with debt-facility covenants.
CME Group Inc. director Martin J. Gepsman sold 400 shares of Class A common stock on October 22, 2026, at $302.50 per share. The sale was reported as a direct transaction, leaving him with 25,244 shares. The transaction description identifies it as a sale in the open market or a private transaction; no Rule 10b5-1 plan is reported.
CME Group Inc. director Martin J. Gepsman reported a proposed sale of 400 common shares, with an aggregate market value of $121,000 and an approximate sale date of October 22, 2026. The notice names Morgan Stanley Smith Barney LLC as the broker and NASDAQ as the exchange.
CME Group Inc. reported Q3 2026 revenue of $1,737.3 million, versus $1,537.6 million in Q3 2025. Operating income was $1,141.4 million, compared with $972.6 million, and net income was $1,036.9 million, versus $908.0 million. Diluted earnings per share were $2.89, compared with $2.49. On an adjusted, non-GAAP basis, operating income was $1,205.5 million, net income was $1,083.9 million and diluted earnings per share were $3.02.
Average daily volume reached a Q3 record of 29.4 million contracts, including 9 million non-U.S. contracts. Clearing and transaction fee revenue was $1,378.1 million, and the average rate per contract was $0.679. Market data revenue was a record $243.1 million, an increase of 20%. CME Group returned nearly $1 billion to shareholders during the quarter, including $465 million in regular quarterly dividends and $524 million in share repurchases.
As of September 30, 2026, CME Group reported $2.4 billion in cash and $3.4 billion of debt.
CME Group Inc. director William R. Shepard reported that his revocable living trust acquired 293 shares at $268.76 per share on September 25, 2026, through a broker-administered dividend reinvestment plan. On August 18, 2026, a 2,554-share transfer changed the form of beneficial ownership from direct to indirect via the trust; direct holdings after the transfer were 1,067 shares.
CME Group Inc. filed a certificate of elimination effective September 24, 2026, removing the provisions for its Series G Non-Voting Convertible Preferred Stock from its certificate of incorporation. No Series G Preferred Stock shares were issued and outstanding when the certificate was filed.
CME GROUP INC. (CME) reported that Julie Winkler, Sr MD Chief Commercial Officer, received an equity award and related tax withholdings in Common Stock Class A.
On September 15, 2026, she acquired 2,864 shares as a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. On September 15 and 16, 2026, a total of 1,413 shares were surrendered to the issuer to satisfy tax withholding obligations in connection with vesting of previously granted restricted stock. No Rule 10b5-1 trading plan is reported.
CME GROUP INC. (CME) reported that Chief Transformation Officer Ken Vroman received an equity compensation award and related tax-withholding share dispositions. On September 15, 2026, he was granted 2,592 shares of Class A common stock as restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. In connection with the vesting of previously granted restricted stock, a total of 1,211 shares of Class A common stock were surrendered to CME Group to satisfy tax withholding obligations on September 15 and 16, 2026. No Rule 10b5-1 trading plan is reported for these transactions.
CME GROUP INC. reported that Jack J. Tobin, its Managing Director and Chief Accounting Officer, received a grant of 700 shares of Class A common stock on September 15, 2026 at $275.09 per share as restricted stock under the CME Group Omnibus Stock Plan. In connection with vesting of previously granted restricted stock, a total of 347 shares of Class A common stock were surrendered to CME Group to satisfy tax withholding obligations on September 15 and 16, 2026 at per-share prices of $275.09 and $272.46, respectively. No Rule 10b5-1 trading plan is reported for these transactions.
CME GROUP INC. (CME) reported that officer Suzanne Sprague, COO & Global Head of Clearing, received an award of 2,864 shares of Class A common stock on September 15, 2026 as restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.
On September 15, 2026 and September 16, 2026, a total of 1,152 shares of Class A common stock were surrendered to CME Group Inc. to satisfy tax withholding obligations related to the vesting of previously granted restricted stock. These transactions were reported as direct ownership and were not made under a Rule 10b5-1 trading plan.